Balances and Transaction with Related Parties (Details Textual) $ in Thousands |
12 Months Ended |
|---|---|
|
Dec. 31, 2020
USD ($)
shares
| |
| Balances and Transaction with Related Parties (Textual) | |
| Loan granted to related party | $ 19 |
| Aggregate of remaining potential commitment | $ 89 |
| Issuance of shares on loan to treasury stock | shares | 5,700 |
| Janssen Research & Development, LLC [Member] | |
| Balances and Transaction with Related Parties (Textual) | |
| Research collaboration agreement, description | BiomX Israel is eligible to receive fees totaling $167 in installments of $50 within 60 days of signing of the agreement, $17 upon completion of data processing, and two installments of $50 each, upon delivery of Signature Phase I of the Final Study Report (both terms defined within the agreement). This agreement ended in 2020, 30 days after the parties completed the research program and BiomX Israel provided Janssen with a final study report. As of December 31, 2019, consideration of $117 had been received. The remaining $50 consideration was received in January 2020. |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of loan granted to related party. No definition available.
|
| X | ||||||||||
- Definition Amount of the fee for available but unused credit capacity under the credit facility. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|